Drug Trial Radar · NCT00044785
Phase I Study of PN401, Fluorouracil, Leucovorin and CPT-11 in Patients With Solid Tumors
Last checked: Nov 20, 2026Latest source record: Jun 24, 2005 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
24
Actual
Start
Aug 2002
Primary completion
Not stated
Study completion Mar 2004
Sponsor
- Lead sponsor
- Wellstat TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Sep 6, 2002
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
CPT-11 and 5Fluorouracil (5FU) combined with leucovorin has become the standard of care for colorectal cancer. PN401 permits treatment with higher than normal doses of 5FU, which could increase its therapeutic potential. It is hypothesized that adding PN401 to the CPT-11, 5FU, leucovorin regimen will reduce toxicity and will allow higher doses of 5FU to be well tolerated and therefore potentially increase effectiveness.
Conditions
- Solid Tumors
Interventions
triacetyluridineDrug
fluorouracilDrug
leucovorinDrug
camptosarDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and Maximum Tolerated Dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Maryland, Greenebaum Cancer Center
Baltimore, Maryland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.